Dyslipidemia in Patients with Androgenetic Alopecia: Statins, Finasteride, or Both?

A meta-analysis of 19 observational studies found that patients with androgenetic alopecia (AGA) have a higher risk of cardiovascular disease due to an atherogenic lipid profile. The study suggests that altered sensitivity to androgens and chronic microinflammation may explain the link between AGA and dyslipidemia. Statins, a class of lipid-lowering drugs, have significant immunomodulating effects that may have a beneficial role in patients with dyslipidemia and AGA. Finasteride, a 5α-reductase inhibitor, may have a moderate influence on the metabolic profile of patients with AGA. Further studies are needed to confirm these initial findings. Dermatologists and primary care physicians should monitor patients with AGA for the development of metabolic syndrome components to reduce cardiovascular risk.